High-dose bevacizumab therapy may lead to less need for retreatment for ROP

For retinopathy of prematurity (ROP), treating with high-dose bevacizumab vs low-dose bevacizumab or any dose of ranibizumab may mean a lower rate of retreatment.
Source: AAO

Posted in: Uncategorized

Leave a response

658 Malta Ave, Suite 101 Malta, NY 12020 (518) 580-0553